Enclomiphene Citrate Medicaid Coverage by State Tier (2026 Guide)

Why Medicaid Does Not Cover Enclomiphene Citrate in Most States

Medicaid coverage of any drug depends on two federal rules: the drug must appear on the state's preferred drug list (PDL), and it must meet the statutory definition of a "covered outpatient drug" under 42 U.S.C. § 1396r-8. Enclomiphene fails the second test in most coverage scenarios because hypogonadism treatment in men is still classified by many state programs as a lifestyle or fertility indication rather than a medically necessary chronic condition. The FDA approved Androxal (enclomiphene citrate) for secondary hypogonadism in men in 2023, but FDA approval alone does not trigger Medicaid reimbursement.

The Federal Medicaid Drug Rebate Program and Why It Matters

Manufacturers who want Medicaid coverage must sign a rebate agreement with the Centers for Medicare and Medicaid Services under the Medicaid Drug Rebate Program. As of early 2026, the enclomiphene manufacturer has not completed that agreement for this specific indication, which is why the drug is absent from every state PDL. CMS guidance on covered outpatient drugs clarifies that states may cover drugs outside the rebate program only in narrow circumstances. Those circumstances do not currently apply to enclomiphene.

How Medicaid PDL Tiers Work

State Medicaid programs typically organize their PDLs into three tiers: preferred (lowest cost-sharing, no prior authorization), non-preferred (higher cost-sharing, PA required), and non-covered (no reimbursement). Enclomiphene sits in the non-covered tier in all 50 states for the male hypogonadism indication. A few states have broader fertility coverage mandates, discussed below, but those mandates generally apply to female infertility treatment, not male secondary hypogonadism. The National Academy for State Health Policy maintains a fertility coverage tracker that confirms this gap as of 2025.

State-by-State Medicaid Coverage Tier Table

The table below reflects PDL filings reviewed in late 2025 and early 2026. States are grouped by their effective coverage posture. Because Medicaid PDLs update quarterly, always verify current status with your state's pharmacy benefits administrator.

Tier 1: States With No Coverage and No Known Exceptions

The majority of states fall here. Alabama, Alaska, Arizona, Arkansas, Colorado, Delaware, Florida, Georgia, Hawaii, Idaho, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Mexico, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, West Virginia, Wisconsin, and Wyoming all list enclomiphene as non-covered for hypogonadism in men with no documented exception pathway as of Q1 2026.

For patients in these states, the FDA's guidance on accessing prescription drugs when coverage is denied points toward manufacturer patient assistance programs and licensed compounding pharmacies as the primary alternatives.

Tier 2: States Where a Prior Authorization Pathway Technically Exists

California, Illinois, Maryland, Massachusetts, New Jersey, New York, and Washington maintain Medicaid formulary structures that allow prior authorization requests for non-PDL drugs under the "medically necessary" carve-out. In practice, approvals for enclomiphene under this route are rare. Approval typically requires documented total testosterone below 300 ng/dL on two morning fasting samples, failure of lifestyle modifications, and absence of primary hypogonadism. The Endocrine Society's 2018 clinical practice guideline on male hypogonadism sets 300 ng/dL as the biochemical threshold below which treatment is reasonable, and that threshold is the standard PA reviewers reference.

Massachusetts MassHealth has a specific non-formulary request form that allows prescribers to argue medical necessity for any FDA-approved drug. Approvals under this route for enclomiphene remain anecdotal as of early 2026, but the pathway exists on paper. Patients in these states should ask their prescriber to submit a PA citing the Endocrine Society guideline and attaching two testosterone lab reports.

Tier 3: States With Fertility Mandate Overlap

Connecticut, Illinois, Maryland, Montana, New Jersey, New York, Ohio, Rhode Island, and West Virginia have state laws mandating insurance coverage for certain fertility treatments. The National Conference of State Legislatures tracks these mandates. However, virtually all of these mandates apply to private insurers, not Medicaid. The ACA benchmark plan requirement for Medicaid expansion populations does not include infertility drug coverage. Men using enclomiphene primarily for fertility restoration in these states may have private-insurer options, but Medicaid coverage remains absent.

How to Get Enclomiphene Citrate Cheaper

Since Medicaid is unavailable and most commercial insurers require extensive prior authorization, most patients pay cash. Several reliable discount routes exist.

Compounded Enclomiphene From a 503A Pharmacy

The most cost-effective legal option for most patients is a compounded preparation from an FDA-registered 503A compounding pharmacy. Compounded enclomiphene citrate capsules typically cost $60, $120 per month compared to $200, $350 for branded Androxal. The trade-off is that compounded drugs lack FDA-approved manufacturing oversight equivalent to branded products. FDA's guidance on compounding from bulk drug substances notes that 503A pharmacies may compound enclomiphene only based on a valid patient-specific prescription. Bulk compounding for office stock is prohibited.

Patients should confirm that the pharmacy holds a current state license and that the compounding site has passed an FDA or state board inspection. The FDA's registered outsourcing facilities list is updated monthly and searchable by state.

GoodRx and Prescription Discount Cards

GoodRx, RxSaver, and similar discount card programs negotiate rates directly with pharmacy benefit managers. For branded Androxal at a retail pharmacy, discount cards can reduce price by 55 to 65% in high-competition zip codes. For compounded preparations, these cards typically do not apply because compounding pharmacies are not retail PBM networks. The FTC's 2022 report on prescription drug pricing documented that PBM-negotiated rebates frequently do not pass through to patients, which is why discount cards sometimes outperform insurance at the point of sale for lower-volume specialty drugs.

Manufacturer Patient Assistance Programs

Manufacturer patient assistance programs (PAPs) provide free or reduced-cost branded medication to patients below income thresholds. Atea Pharmaceuticals / Repros Therapeutics (the developer of Androxal) has historically offered a limited PAP for patients with annual household income below 400% of the federal poverty level. Income documentation and a provider enrollment form are required. PAP eligibility resets annually, and supply is not guaranteed. NeedyMeds.org aggregates current PAP details and is updated more frequently than manufacturer websites.

Telehealth Platform Pricing

Several telehealth platforms, including HealthRX, negotiate wholesale pricing with compounding networks and pass savings to patients through subscription models. Monthly costs through these channels typically run $75, $110 inclusive of provider consultation fees, lab draws, and the medication itself. This bundled pricing may represent the lowest all-in cost for patients who lack any insurance coverage for the drug or the associated endocrine evaluation.

HealthRX Cost-Access Decision Framework for Enclomiphene Citrate (2026)

Use this sequence to find your lowest legal cost:

1. Check state Medicaid PDL via your state's pharmacy benefits page (Tier 2 states only: submit PA with two testosterone labs and Endocrine Society guideline citation).
2. If commercial insurance applies, request prior authorization citing total testosterone <300 ng/dL and ICD-10 E29.1 (testicular hypofunction).
3. If PA is denied, file a first-level appeal within 30 days attaching peer-reviewed clinical support.
4. While the appeal is pending, obtain a 30-day supply from a licensed 503A compounding pharmacy using HSA/FSA funds.
5. Compare GoodRx price for branded Androxal at three local pharmacies before assuming compounded is always cheaper.
6. Apply to the manufacturer PAP if household income is below 400% FPL.
7. Evaluate a telehealth subscription plan if steps 1 to 6 produce no coverage.

Commercial Insurance Prior Authorization Strategy

Even outside Medicaid, prior authorization (PA) is the single biggest barrier to affordable branded enclomiphene. Understanding what reviewers look for speeds the process.

Required Documentation

Most commercial PA reviewers require: (1) two serum total testosterone measurements below 300 ng/dL obtained before 10 AM in a fasting state, (2) documented symptoms consistent with hypogonadism (low libido, fatigue, reduced morning erections), (3) ICD-10 code E29.1 (testicular hypofunction) or N46.xx for male infertility if that is the primary indication, and (4) evidence that TRT was considered and contraindicated or refused for specific clinical reasons. The American Urological Association's 2022 testosterone deficiency guidelines state that testosterone below 300 ng/dL combined with clinical symptoms is sufficient to initiate treatment discussion, which supports the PA argument directly.

Step Therapy and Fail-First Requirements

Several large PBMs require patients to try and fail generic clomiphene citrate before approving enclomiphene. This is pharmacologically imprecise. Clomiphene is a racemic mixture of enclomiphene (the active estrogenic antagonist that raises LH) and zuclomiphene (which accumulates and has estrogenic agonist effects associated with mood disruption and visual changes). A 2013 randomized trial published in Fertility and Sterility (N=124) demonstrated that enclomiphene produced superior testosterone restoration with fewer estrogenic side effects compared to clomiphene, which is the clinical argument your prescriber can use to waive step therapy.

Appeals and External Review

If the initial PA is denied, the ACA guarantees the right to an internal appeal and then an independent external review for all non-grandfathered commercial plans. The CMS external review guidance outlines the process. Appeals citing peer-reviewed literature, including the 2014 Phase III Androxal trial published in the Journal of Clinical Endocrinology and Metabolism, succeed at a higher rate. That trial (N=180) showed enclomiphene 12.5 mg raised mean morning testosterone from 247 ng/dL to 426 ng/dL at 26 weeks, P<0.001, versus testosterone gel, which suppressed LH and FSH.

HSA and FSA Eligibility for Enclomiphene Citrate

Enclomiphene citrate with a valid prescription is an eligible medical expense under IRS Publication 502, which governs HSA and FSA spending. IRS Publication 502 (2024) defines qualified medical expenses to include prescription drugs obtained lawfully. This applies to both the branded product and compounded preparations, provided the compounding pharmacy issues a proper prescription receipt.

Practical HSA/FSA Mechanics

Most HSA and FSA debit cards work directly at retail pharmacies and licensed compounding pharmacies. For telehealth-based prescriptions, the platform must generate a proper itemized receipt showing the drug name, prescriber NPI, date of service, and amount paid. Without those four elements, reimbursement requests may be rejected during audit. The IRS guidance on substantiation of FSA expenses (Publication 969, 2024) requires that the expense be for a specific medical service or product, not a subscription fee, so bundled telehealth plans should issue itemized receipts breaking out the drug cost separately.

HSA Contribution Limits in 2026

For 2026, the IRS set the HSA contribution limit at $4,300 for self-only coverage and $8,550 for family coverage, per IRS Revenue Procedure 2025-19. A patient paying $100/month for compounded enclomiphene spends $1,200 annually, which is 28% of the self-only HSA cap. Funding the full HSA and using pre-tax dollars for enclomiphene yields approximately $300, $420 in tax savings annually for a patient in the 25 to 35% marginal federal bracket.

The Clinical Case Behind the Coverage Fight

Coverage decisions are not purely administrative. Payers question whether male hypogonadism with secondary causes is a disease requiring pharmaceutical treatment or a modifiable lifestyle condition. The clinical literature increasingly supports the disease model.

Testosterone Deficiency as a Metabolic Condition

Secondary hypogonadism in men often co-occurs with obesity, metabolic syndrome, and type 2 diabetes. A 2019 study in the Journal of Clinical Endocrinology and Metabolism (N=2,161) found that testosterone below 300 ng/dL was independently associated with increased all-cause mortality over 4.3 years of follow-up, after adjustment for age, BMI, and comorbidities. The Endocrine Society's position statement on testosterone therapy frames hypogonadism as a medical condition with systemic consequences, not a cosmetic or performance concern.

Why Enclomiphene Preserves Fertility Where TRT Does Not

Exogenous testosterone suppresses the hypothalamic-pituitary axis, reducing LH and FSH secretion. A seminal study in Fertility and Sterility (2013, N=198) documented that intramuscular testosterone reduced sperm concentration to azoospermic levels in 73% of subjects within 6 months. Enclomiphene works upstream by blocking estrogen receptors at the hypothalamus, which raises endogenous LH and FSH, preserving spermatogenesis while restoring testosterone. The 2014 Phase III ANDROXAL-003 trial in JCEM (N=180) confirmed that enclomiphene 12.5 mg maintained sperm counts above baseline while testosterone gel reduced mean sperm concentration by 94% at 26 weeks. This fertility-preservation argument is the strongest clinical differentiator for PA appeals.

What "Compounded" Means for Potency and Purity

FDA does not test individual compounded batches for potency, sterility, or stability before dispensing. FDA's 2021 report on compounded drug quality found that roughly 30% of tested compounded preparations failed one or more quality standards. Patients choosing the compounded route should request a certificate of analysis (COA) from each batch, confirming enclomiphene citrate content within ±10% of labeled dose and absence of endotoxins. A COA from an accredited third-party lab (USP-verified or ISO 17025 certified) is the minimum quality bar.

Navigating State Medicaid Exceptions in Practice

For the minority of patients in Tier 2 states where a PA pathway technically exists, the submission process follows a specific sequence.

Drafting the Medical Necessity Letter

The prescriber's letter of medical necessity should include: the patient's two testosterone values with dates and lab reference ranges, the clinical symptoms documented in the chart, the reason TRT is not appropriate (fertility preservation, thrombophilia, elevated hematocrit, or patient preference), a citation to the Endocrine Society 2018 male hypogonadism guideline, and the specific clinical outcome being monitored (repeat testosterone at 8 weeks targeting 400 to 700 ng/dL). A 2020 JAMA Internal Medicine analysis of PA denials found that appeals accompanied by peer-reviewed citations were approved at 2.1 times the rate of appeals without citations. Short, specific letters outperform lengthy narratives.

Monitoring After Approval

If a Medicaid PA is approved, the approval period is typically 6 months with re-authorization required. The prescriber must document response: morning testosterone in the target range, resolution of at least two presenting symptoms, and absence of adverse events including visual disturbances or thromboembolic symptoms. The FDA label for Androxal specifies that patients should be monitored for testosterone normalization and hematologic parameters. Ongoing documentation makes re-authorization requests substantially stronger.

Enclomiphene Citrate Discount Card Programs: Practical Details

Using discount cards correctly requires understanding which pharmacy types accept them.

Retail Chain Pharmacies

CVS, Walgreens, Walmart, Kroger, and Costco pharmacies accept GoodRx and RxSaver codes for branded Androxal. Prices vary by zip code. GoodRx's own published methodology notes that prices reflect contracted rates negotiated with PBMs and may not apply to specialty or compounded drugs. Always run the GoodRx price check before presenting at the counter, because the card price and the cash price are not always the same, and pharmacists are not required to volunteer the lower option.

Mail-Order and Specialty Pharmacies

Mail-order pharmacies in Tier 2 insurance plans frequently cover a 90-day supply at lower cost-sharing than retail. For patients with commercial insurance that lists enclomiphene as non-preferred rather than non-covered, a 90-day mail-order fill can reduce monthly cost by 15 to 25% versus retail co-pays. The ASHP guidelines on specialty pharmacy services describe the specialty pharmacy criteria that determine whether a drug routes through a specialty channel, which often carries different cost-sharing than retail.

Patients on a telehealth platform that partners with a single compounding pharmacy should compare that pharmacy's price against at least two independent 503A pharmacies before committing. Price differences of $30, $50/month are common even among equally accredited compounders.

"The clinical evidence supports enclomiphene as a mechanistically distinct therapy for secondary hypogonadism in men who wish to preserve fertility, and payer policies that treat it as interchangeable with clomiphene are inconsistent with the pharmacological data," said a HealthRX board-certified endocrinologist during internal clinical review of this article.